Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T
Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.
Clin Cancer Res. 1998 Mar;4(3):659-64.
The circulating hepatocyte growth factor (HGF)/scatter factor level is frequently increased in advanced cancer patients. In this study, we have assessed the prognostic value of the circulating HGF level determined by enzymatic immunoassay in primary breast cancer patients. Of 200 primary breast cancer patients, 54 (27.0%) showed the increase of serum HGF level according to the age-matched cutoff values. The prognosis of the patients with the increased HGF level was statistically worse than that of the patients with normal HGF level (P = 0.0001, log-rank test). Multivariate analysis confirmed that the increase in HGF level was an independent prognostic indicator in primary breast cancer patients. In the background analysis, the increase in serum HGF level was significantly associated with tumor size, nodal status, and histological evidence of venous invasion. The data indicate that up-regulation of the circulating HGF level may predict systemic tumor spread and early relapse in primary breast cancer patients.
晚期癌症患者循环中的肝细胞生长因子（HGF）/分散因子水平常常升高。在本研究中，我们评估了通过酶免疫测定法测定的循环HGF水平在原发性乳腺癌患者中的预后价值。在200例原发性乳腺癌患者中，根据年龄匹配的临界值，54例（27.0%）血清HGF水平升高。HGF水平升高患者的预后在统计学上比HGF水平正常的患者差（P = 0.0001，对数秩检验）。多变量分析证实，HGF水平升高是原发性乳腺癌患者的独立预后指标。在背景分析中，血清HGF水平升高与肿瘤大小、淋巴结状态及静脉侵犯的组织学证据显著相关。数据表明，循环HGF水平上调可能预示原发性乳腺癌患者的全身肿瘤播散和早期复发。
